Menu

RIKEN Head Leaving Early

Ryoji Noyori is stepping down from his post as the leader of the premier Japanese research institute before his tenure expires.

Mar 10, 2015
Kerry Grens

WIKIMEDIA, ??????????:BRUNEIThe president of the RIKEN research institute in Japan, Ryoji Noyori, will resign this month, according to news reports. He was slated to hold the position for another three years.

According to Asahi Shimbun, Noyori cited his age and his many years already spent serving as RIKEN’s president as part of his decision to leave. Noyori also recently weathered considerable turmoil at RIKEN over scientific misconduct regarding a stem cell technique and the suicide of an involved investigator. However, education “[m]inistry officials said that he is not resigning to take responsibility for the recent scandal,” Asahi Shimbun reported.

The 76-year-old Nobel laureate has led RIKEN for more than a decade. The Ministry is searching for his replacement.

Hat tip: ScienceInsider

Correction (March 12): The first sentence originally stated that Ryoji Noyori said he will resign; rather, education ministry officials made the announcement. The RIKEN press office has not received confirmation of his resignation. The Scientist regrets the error.

Update (March 24): Nature reported today that Noyori has resigned. His successor will be physicist Hiroshi Matsumoto.

January 2019

Cannabis on Board

Research suggests ill effects of cannabinoids in the womb

Marketplace

Sponsored Product Updates

Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery extends CRISPR Screening Service to primary human T cells
Horizon Discovery Group plc (LSE: HZD) (“Horizon” or “the Company”), a global leader in gene editing and gene modulation technologies, today announced the extension of its CRISPR Screening Service to includeex vivoT lymphocytes. The service extension meets the requirements of immunology-based research in drug discovery,enabling new gene targets to be identified in biologically and potentially therapeutically relevant settings.
pIC50: The Advantages of Thinking Logarithmically
pIC50: The Advantages of Thinking Logarithmically
Watch this webinar from Collaborative Drug Discovery to learn about how using pIC50 helps you get a better sense of the relative potencies, calculate the correct mean of multiple values, and select better sampling doses.
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
WIN a VIAFLO 96/384 to supercharge your microplate pipetting!
INTEGRA Biosciences is offering labs the chance to win a VIAFLO 96/384 pipette. Designed to simplify plate replication, plate reformatting or reservoir-to-plate transfers, the VIAFLO 96/384 allows labs without the space or budget for an expensive pipetting robot to increase the speed and throughput of routine tasks.
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX® digital PCR technology to be acquired by QIAGEN
FORMULATRIX has announced that their digital PCR assets, including the CONSTELLATION® series of instruments, is being acquired by QIAGEN N.V. (NYSE: QGEN, Frankfurt Stock Exchange: QIA) for up to $260 million ($125 million upfront payment and $135 million of milestones).  QIAGEN has announced plans for a global launch in 2020 of a new series of digital PCR platforms that utilize the advanced dPCR technology developed by FORMULATRIX combined with QIAGEN’s expertise in assay development and automation.